BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37975903)

  • 1. PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room.
    Raghav KPS; Loree JM; Kopetz S
    Clin Cancer Res; 2024 Jan; 30(2):260-262. PubMed ID: 37975903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
    De Cuyper A; Van Den Eynde M; Machiels JP
    Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
    Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study.
    Randon G; Nakamura Y; Yaeger R; Lonardi S; Cremolini C; Elez E; Nichetti F; Ghelardi F; Nasca V; Bergamo F; Conca V; Ros J; Bando H; Maddalena G; Oldani S; Prisciandaro M; Raimondi A; Schrock AB; Agnelli L; Walch H; Yoshino T; Pietrantonio F
    Clin Cancer Res; 2024 Jan; 30(2):436-443. PubMed ID: 37610454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
    Ross JS; Fakih M; Ali SM; Elvin JA; Schrock AB; Suh J; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Sun J; Miller VA; Stephens PJ; Gay LM
    Cancer; 2018 Apr; 124(7):1358-1373. PubMed ID: 29338072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.
    Shimada Y; Yagi R; Kameyama H; Nagahashi M; Ichikawa H; Tajima Y; Okamura T; Nakano M; Nakano M; Sato Y; Matsuzawa T; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Kawasaki T; Homma KI; Izutsu H; Kodama K; Ring JE; Protopopov A; Lyle S; Okuda S; Akazawa K; Wakai T
    Hum Pathol; 2017 Aug; 66():1-9. PubMed ID: 28235632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine.
    Valentini AM; Cavalcanti E; Di Maggio M; Caruso ML
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):539-544. PubMed ID: 30199395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
    Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T
    J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
    Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
    Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.
    Sandhu J; Wang C; Fakih M
    J Natl Compr Canc Netw; 2020 Feb; 18(2):116-119. PubMed ID: 32023524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.
    Wang G; He Y; Sun Y; Wang W; Qian X; Yu X; Pan Y
    Clin Transl Oncol; 2020 Jun; 22(6):813-822. PubMed ID: 31587152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative Hyperselection of Patients With
    Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F
    J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
    Meric-Bernstam F; Hurwitz H; Raghav KPS; McWilliams RR; Fakih M; VanderWalde A; Swanton C; Kurzrock R; Burris H; Sweeney C; Bose R; Spigel DR; Beattie MS; Blotner S; Stone A; Schulze K; Cuchelkar V; Hainsworth J
    Lancet Oncol; 2019 Apr; 20(4):518-530. PubMed ID: 30857956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab.
    Liu R; Zhao X; Guo W; Huang M; Qiu L; Zhang W; Zhang Z; Li W; Zhu X; Chen Z
    Clin Transl Oncol; 2020 Jun; 22(6):928-934. PubMed ID: 31571151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target.
    Ahcene Djaballah S; Daniel F; Milani A; Ricagno G; Lonardi S
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-14. PubMed ID: 35580290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Truncal Dynamics May Trump: Serial ctDNA to Predict Early Therapeutic Response.
    Eluri M; Kopetz S; Parseghian CM
    Clin Cancer Res; 2023 Jan; 29(2):302-304. PubMed ID: 36378102
    [TBL] [